Lung Cancer
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global lung cancer drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 1–12 of 24 articles
Quick answer
NovaPharmaNews Lung Cancer hub for FDA covers 24 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Arcus Biosciences pipeline update: casdatifan, quemliclustat, domvanalimab
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
China’s Rise in Drug Development Looms Over U.S. Oncology Market
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Akeso and Summit Drug Shows Promise in Lung Cancer Trial
China Approves HERNEXEOS for Lung Cancer Treatment
Latest Insights on Parkinson’s Drug Setback and Merck’s Lung Cancer Therapy
#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck
Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%
Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.